Daaweynta CAR-T ee loogu talagalay Myasthenia Gravis (MG)

Myasthenia Gravis (MG) waa xanuun daba-dheeraada oo ku dhaca neerfaha muruqyada oo ay keento unugyada difaaca jirka (oo inta badan ka hortagga acetylcholine receptor antibodies, AchRAb) kaas oo wiiqa isgaarsinta u dhaxaysa neerfayaasha iyo muruqyada, taasoo keenta daciifnimo isbedbeddelaysa, ptosis, dysphagia, iyo xaaladaha daran ee neefsashada oo halis gelinaysa nolosha. Bukaannada qaba MG aan firfircoonayn oo ku guuldareysta daawooyinka difaaca jirka ee caadiga ah, IVIG, FcRn inhibitors, iyo kuwa ka hortagga dhammaystirka, fursadaha daaweyntu way xaddidan yihiin.

Daaweynta laba-bartilmaameed ee BIOOCUS ee CD19/BCMA CAR-T waxay ka dhigan tahay daaweyn unug oo otomaatig ah oo horumarsan oo si sax ah u baabi'isa unugyada B ee cudurada keena iyo unugyada plasma ee mas'uulka ka ah soo saarista unugyada difaaca jirka, taasoo bixinaysa fursadda cafis qoto dheer oo waara oo ku dhacda MG-da adag in la daweeyo.

Daaweynta CAR-T ee MG waa daaweyn difaac oo heer sare ah oo shaqsiyeysan kaas oo unugyada T ee bukaanka loo sameeyay si hidde ahaan loogu farsameeyay inay muujiyaan soo-dhoweeyayaasha antigen-ka chimeric (CARs) oo bartilmaameedsanaya labadaba CD19 (unugyada B) iyo BCMA (unugyada plasma). Ka dib marka la ballaariyo shaybaarka, unugyadan CAR-T ee laba-bartilmaameedsan ayaa dib loogu shubaa bukaanka, halkaas oo ay si gaar ah u baabi'iyaan unugyada difaaca jirka ee firfircoon ee wada MG, taasoo yareyneysa heerarka AchRAb iyo soo celinta shaqada neerfaha.

Habkan laba-bartilmaameedku wuxuu wax ka qabanayaa qaybaha unugyada iyo kuwa humoral ee jawaabta isdifaaca jirka, isagoo bixinaya dib-u-habeyn dhammaystiran oo nidaamka difaaca jirka ah marka loo eego daaweynta hal-bartilmaameed ama dhaqameed.

• Horumar degdeg ah oo joogto ah oo calaamadaha ah: Hoos u dhac weyn oo ku yimaada daalka murqaha, ptosis, diplopia, dysarthria, iyo daciifnimada addimada.
• Yaraanshaha qoto dheer ee unugyada B iyo unugyada balaasmaha: Hoos u dhac calaamadeysan oo waara oo ku yimaada tirada AchRAb iyo wadarta guud ee B-lymphocyte.
• Dhibcaha caafimaad ee la hagaajiyay: Faa'iidooyin la taaban karo oo laga helay dhibcaha Quantitative Myasthenia Gravis (QMG) iyo Activity of Daily Living (ADL).
• Astaanta badbaadada ee wanaagsan: Si fiican ayaa loo dulqaatay iyada oo aan la helin cillad sii daynta cytokine (CRS) ama sunta neerfaha ee lagu arkay kiisaska la daaweeyay.
• Suurtagalnimada cafinta muddada dheer: Waxay yareysaa ama baabi'isaa baahida loo qabo joojinta difaaca jirka ee joogtada ah.
• Shakhsiyeysan oo sax ah: Waxay isticmaashaa unugyada bukaanka, taasoo yaraynaysa khatarta diidmada.

1. Leukapheresis– Ururinta unugyada T ee bukaanka iyada oo loo marayo apheresis dhiig oo ku wareegsan.
2. Injineernimada Hiddaha- Unugyada T waxaa wax laga beddelay si ay u muujiyaan CD19 iyo BCMA CARs waxaana lagu ballaariyay xarumaha GMP.
3. Qaboojinta (haddii loo baahdo)- Limfa yar oo kooban si loo hagaajiyo qorista CAR-T.
4. Faleebo CAR-T ah– Faleebo hal mar ah oo xididka CD19 CAR-T ah (0.5×10⁶/kg) + BCMA CAR-T (1×10⁶/kg).
5. La socodka iyo Dabagalka- Qiimayn joogto ah oo ku saabsan ballaarinta CAR-T, heerarka AchRAb, tirinta unugyada B, dhibcaha QMG/ADL, iyo shaqada xubnaha ilaa 12+ bilood.

• Madal laba-bartilmaameed CD19/BCMA CAR-T ah oo heer sare ah oo si gaar ah loogu habeeyay cudurada difaaca jirka.
• Kooxda wax soo saarka GMP ee heer caalami ah iyo kooxda daaweynta difaaca jirka ee khibradda leh oo leh khibrad ku saabsan kansarka dhiigga iyo xaaladaha difaaca jirka ee aan iska caabin karin.
• Taageero bukaan oo caalami ah oo dhammaystiran: isku-dubarid luqado badan leh, wareejinta garoonka diyaaradaha, hoyga, iyo dabagalka muddada dheer.
• Rikoor la xaqiijiyay oo ku jira CAR-T ee cudurada difaaca jirka (oo ay ku jiraan SLE) iyo qorsheynta daaweynta shaqsiyeed.
• Daryeelka buuxa laga bilaabo qiimeynta daaweynta ka hor ilaa la socodka tallaalka ka dib.